Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prospects for the Potential of Rna Interference in the Treatment of Autoimmune Diseases: Small Interfering Rnas in the Spotlight Publisher Pubmed



Gorabi AM1 ; Kiaie N1 ; Aslani S2 ; Jamialahmadi T3, 4, 5 ; Johnston TP6 ; Sahebkar A7, 8, 9, 10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran
  5. 5. Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  6. 6. Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, United States
  7. 7. Halal Research Center of IRI, FDA, Tehran, Iran
  8. 8. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  9. 9. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran
  10. 10. Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

Source: Journal of Autoimmunity Published:2020


Abstract

The identification of RNA interference (RNAi) has caused a growing interest in harnessing its potential in the treatment of different diseases. Modulation of dysregulated genes through targeting by RNAi represents a potential approach with which to alter the biological pathways at a post-transcriptional level, especially as it pertains to autoimmunity and malignancy. Short hairpin RNAs (shRNA), short interfering RNAs (siRNA), and microRNAs (miRNA) are mainly involved as effector mechanisms in the targeting of RNAi biological pathways. The manipulation and delivery of these molecules in an efficient way promotes the specificity and stability of RNAi-based systems, while minimizing the unwanted adverse reactions by the immune system and reducing cytotoxicity and off-target effects. Advances made to date in identifying the etiopathogenesis of autoimmune diseases has prompted the utilization of RNAi-based systems in vitro and in vivo. Future investigations aimed at deciphering the molecular basis of RNAi and optimizing the delivery of RNAi-based targeting systems will hopefully promote the applicability of such regulatory mechanisms and, ultimately, transfer the acquired knowledge from bench-to-bedside to ameliorate human diseases. In this review, we seek to clarify the potential of RNAi, with a focus on siRNAs, in designing therapeutics for potential treatment of human autoimmune disorders. © 2020 Elsevier Ltd
Other Related Docs